These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15547037)

  • 1. Impact of glycaemic and lipid control on outcome after percutaneous coronary interventions in diabetic patients.
    Briguori C; Condorelli G; Airoldi F; Mikhail GW; Ricciardelli B; Colombo A
    Heart; 2004 Dec; 90(12):1481-2. PubMed ID: 15547037
    [No Abstract]   [Full Text] [Related]  

  • 2. Glycemic control is another target of PCI in diabetic patients--to improve clinical outcome from outside the procedure.
    Fujita H; Nagai R
    Circ J; 2011; 75(4):773-4. PubMed ID: 21427502
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications.
    Kesavulu MM; Giri R; Kameswara Rao B; Apparao C
    Diabetes Metab; 2000 Nov; 26(5):387-92. PubMed ID: 11119018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summaries for patients. The relationship between blood sugar control and cardiovascular disease in patients with diabetes.
    Ann Intern Med; 2004 Sep; 141(6):I21. PubMed ID: 15381537
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study.
    Hasslacher C
    J Diabetes Complications; 1996; 10(3):136-8. PubMed ID: 8807458
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions.
    Kornowski R; Fuchs S
    J Am Coll Cardiol; 2004 Jan; 43(1):15-7. PubMed ID: 14715175
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of glycemic and lipid achievements on clinical outcomes type 2 diabetic, Chinese patients with stable coronary artery disease.
    Li S; Zhang Y; Guo YL; Zhu CG; Wu NQ; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
    J Diabetes Complications; 2016; 30(1):115-20. PubMed ID: 26481154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status in achievement of glycaemic, lipid and blood pressure goals in type 2 diabetic patients with coronary artery disease.
    Gikas A; Sotiropoulos A; Tsakountakis N; Michalis D; Papazafiropoulou A; Pastromas V
    Hellenic J Cardiol; 2009; 50(6):552-4. PubMed ID: 19942571
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk factor control for coronary artery disease secondary prevention in large randomized trials.
    Farkouh ME; Boden WE; Bittner V; Muratov V; Hartigan P; Ogdie M; Bertolet M; Mathewkutty S; Teo K; Maron DJ; Sethi SS; Domanski M; Frye RL; Fuster V
    J Am Coll Cardiol; 2013 Apr; 61(15):1607-15. PubMed ID: 23500281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between plasma adrenomedullin levels and metabolic control, risk factors, and diabetic microangiopathy in patients with type 2 diabetes.
    Turk HM; Buyukberber S; Sevinc A; Ak G; Ates M; Sari R; Savli H; Cigli A
    Diabetes Care; 2000 Jun; 23(6):864-7. PubMed ID: 10841017
    [No Abstract]   [Full Text] [Related]  

  • 11. [Revascularization of coronary artery disease in diabetes mellitus].
    Wexberg P; Weidinger F
    Wien Med Wochenschr; 2010 Jan; 160(1-2):40-3. PubMed ID: 20229160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor.
    Gerstein HC
    Ann Intern Med; 2004 Sep; 141(6):475-6. PubMed ID: 15381522
    [No Abstract]   [Full Text] [Related]  

  • 13. Independent correlation between plasma lipoprotein(a) and angiographic coronary artery disease in NIDDM.
    Watts GF; ap Gwilym RM; Mazurkiewicz J; Coltart J
    Diabetes Care; 1995 Feb; 18(2):234-6. PubMed ID: 7729303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum lipoprotein(a) is increased in hypertensive NIDDM patients.
    Hancu N; Netea MG; Iancu S
    Diabetes Care; 1995 Jun; 18(6):879-80. PubMed ID: 7555518
    [No Abstract]   [Full Text] [Related]  

  • 15. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
    Kautzky-Willer A; Kamyar MR; Gerhat D; Handisurya A; Stemer G; Hudson S; Luger A; Lemmens-Gruber R
    Gend Med; 2010 Dec; 7(6):571-83. PubMed ID: 21195357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in composite control of cardiovascular risk factors among patients with type 2 diabetes.
    Strom Williams JL; Lynch CP; Winchester R; Thomas L; Keith B; Egede LE
    Diabetes Technol Ther; 2014 Jul; 16(7):421-7. PubMed ID: 24735058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.
    Nielsen FS; Voldsgaard AI; Gall MA; Rossing P; Hommel E; Andersen P; Dyerberg J; Parving HH
    Diabetologia; 1993 May; 36(5):438-44. PubMed ID: 8314449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Patients With Diabetes Having Normal Coronary Arteries.
    Binbrek AS; Ali SM; Baslaib FO; Ali AA
    Angiology; 2015 Jul; 66(6):578-83. PubMed ID: 25092679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HLD-cholesterol and LDL-cholesterol in the blood in type I and II diabetes mellitus and the relation to atherogenesis].
    Felt V
    Vnitr Lek; 1986 Nov; 32(11):1066-72. PubMed ID: 3798773
    [No Abstract]   [Full Text] [Related]  

  • 20. Vascular complications of patients in Kuwait with type 2 diabetes mellitus (NIDDM) and elevated serum lipid peroxides.
    Lanham RJ; Armstrong D; Abdella N
    Adv Exp Med Biol; 1994; 366():433-5. PubMed ID: 7771283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.